Loading...
Please wait, while we are loading the content...
Similar Documents
Adjuvante Chemotherapie beim primären Mammakarzinom
| Content Provider | Semantic Scholar |
|---|---|
| Author | Harbeck, N. |
| Copyright Year | 2003 |
| Abstract | Adjuvant Chemotherapy in Primary Breast Cancer Adjuvant chemotherapy reduces the relative risk of relapse by about 25% – independent of the nodal status. Anthracycline-containing regimens are considered standard for adjuvant chemotherapy. In single studies, superiority to CMF has only been shown for anthracyclinecontaining polychemotherapies with at least three substances or a sequential anthracycline-CMF therapy. Recent data show that adding taxanes to anthracyclinecontaining regimens may lead to significant survival advantages. Based on trial results published so far, taxanes are a valid adjuvant therapy option in node-positive breast cancer. In Germany, their optimal use is currently being evaluated in several clinical trials (i.e. NNBC-3, ECDoc, ADEBAR). Up-to-date evidence-based therapy recommendations for adjuvant chemotherapy can be found in the S2 guidelines of the working group on gynecological oncology (AGO) expert panel ’breast‘ (www.agoonline.de) [1]. Schlüsselwörter Polychemotherapy · Anthrazykline · CMF · Taxane · Mammakarzinom |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://mediatum.ub.tum.de/doc/1218916/document.pdf |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Anthracyclines Chemotherapy, Adjuvant Freund's Adjuvant Gynecologic Oncology Gynecology Infantile Colic List of content management frameworks Mammary Neoplasms Pharmaceutical Adjuvants Polychemotherapy Scientific Publication Taxanes cyclophosphamide/fluorouracil/methotrexate protocol |
| Content Type | Text |
| Resource Type | Article |